ERBB2 and neoplasm: Indeed, until recently, anti-HER2 treatments were exclusively reserved for patients with the ERBB2 amplification (defined by HER2 IHC 3+ or 2+ with ISH positivity) and no clinical benefits were highlighted for patients with HER2-low tumours [17, 19, 25].